CytomX and Regeneron Expand Bispecific Cancer Therapy Collaboration with New Targets
CytomX Therapeutics and Regeneron Pharmaceuticals have expanded their ongoing research collaboration focused on developing tumor-activated bispecific cancer therapy candidates, broadening the scope of an agreement that was originally established in 2019 …